Safety and Effectiveness of Sedation With Adjunctive Ketamine Versus Nonketamine Sedation in the Medical Intensive Care Unit

Abstract

Background:

Ketamine, an N-methyl-d-aspartate receptor antagonist with sedative and analgesic properties, is becoming more popular as an adjunctive sedative in the critically ill patients.

Methods:

We conducted a single center, retrospective cohort study of patients admitted to the medical intensive care unit (MICU) between 2013 and 2018. Patients who received continuous infusion ketamine or nonketamine sedatives (NKS) including dexmedetomidine, fentanyl, midazolam, or propofol were identified. The primary outcome was percentage of Richmond Agitation-Sedation Scale (RASS) scores at goal in patients receiving ketamine as adjunct to NKS compared to those on NKS alone.

Results:

A total of 172 patients were included (n = 86 ketamine, n = 86 NKS). Baseline characteristics were similar with the exception of antipsychotic use, which was higher in the ketamine group (P = .008). Percentage of RASS scores at goal was not different between groups (78.7% vs 81.4%, P = .29). Fewer patients in the ketamine group received continuous infusion fentanyl (76.7% vs 94.2%, P = .002). Patients on adjunctive ketamine required fewer days of intermittent benzodiazepines (0 [0-1] vs 1 [1-2], P < .0001). Patients receiving ketamine required less norepinephrine, receiving a median of 6.32 mg (2.4-20) versus 11.7 mg (5.2-45.2; P = .03). There was no difference in receipt of new antipsychotics or occurrence of arrhythmias.

Conclusion:

Addition of ketamine did not increase the percentage of RASS scores at goal versus NKS but was well tolerated. Ketamine was associated with reductions in norepinephrine requirements, days of intermittent benzodiazepine administration, and number of patients receiving continuous infusion fentanyl. Continuous infusion ketamine appears safe and effective for sedation in the MICU.

Keywords

ketamine sedation agitation pain intensive care

Get full access to this article

View all access options for this article.

References

Sessler

Varney

. Patient-focused sedation and analgesia in the ICU. Chest. 2008;133(2):552–565.

Ely

Shintani

Truman

, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291(14):1753–1762.

Shehabi

Riker

Bokesch

, et al. SEDCOM Study Group. Delirium duration and mortality in lightly sedated, mechanically ventilated intensive care patients. Crit Care Med. 2010;38(12):2311–2318.

Pisani

Kong

Kasl

, et al. Days of delirium are associated with 1-year mortality in an older intensive care unit population. Am J Respir Crit Care Med. 2009;180(11):1092–1097.

Lat

McMillian

Taylor

, et al. The impact of delirium on clinical outcomes in mechanically ventilated surgical and trauma patients. Crit Care Med. 2009;37(6):1898–1905.

Mion

Villevielle

. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19(6):370–380.

Devlin

Skrobik

Gelinas

. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825–e873.

Gao

Rejaei

Liu

. Ketamine use in clinical practice. Acta Pharmacol Sin. 2016;37(7):865–872.

Bourgoin

Albanèse

Wereszczynski

, et al. Safety of sedation with ketamine in severe head injury patients: comparison with sufentanil. Crit Care Med. 2003;31(3):711–717.

10.

Bourgoin

Albanèse

Léone

, et al. Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. Crit Care Med. 2005;33(5):1109–1113.

11.

Kolenda

Gremmelt

Rading

, et al. Ketamine for analgosedative therapy in intensive care treatment of head-injured patients. Acta Neurochir. 1996;138(10):1193–1199.

12.

Garber

Droege

Carter

, et al. Continuous infusion ketamine for adjunctive analgosedation in mechanically ventilated, critically ill patients. Pharmacotherapy. 2019;39(3):288–296.

13.

Groetzinger

Rivosecchi

Bain

, et al. Ketamine infusion for adjunct sedation in mechanically ventilated adults. Pharmacotherapy. 2018;38(2):181–188.

14.

Jakob

Ruokonen

Grounds

, et al. Dexmedetomidine for Long-Term Sedation Investigators. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012;307(11):1151–1160.

15.

Riker

Shehabi

Bokesch

, et al. SEDCOM (Safety and efficacy of dexmedetomidine compared with midazolam) study group. dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(5):489–499.

16.

Pruskowski

Harbourt

Pajoumand

, et al. Impact of ketamine use on adjunctive analgesic and sedative medications in critically ill trauma patients. Pharmacotherapy. 2017;37(12):1537–1544.

17.

Green

. Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. Acad Emerg Med. 2000;7(3):278–281.

18.

Perbet

Verdonk

Godet

, et al. Low doses of ketamine reduce delirium but not opiate consumption in mechanically ventilated and sedated ICU patients: a randomized double-blind control trial. Anaesth Crit Care Pain Med. 2018;37(6):589–595.

19.

Umunna

Tekwani

Barounis

, et al. Ketamine for continuous sedation of mechanically ventilated patients. J Emerg Trauma Shock. 2015;8(1):11–15.